To visualize and estimate individual patients’ prognosis, we developed a nomogram to predict the 1-, 3-, and 5-year survival rates of UCEC patients based on several factors, including Age, BMI, Clinical stage, Histological type, Primary therapy outcome, Residual tumor, Histologic grade, Tumor invasion, Menopause status, Hormone therapy, CDKN2B-AS1, IGF2BP, and hsa-miR-497-5p. This evidence concerns the gene CDKN2B and neoplasm.